Results 81 to 90 of about 15,817 (237)

Identifying Knowledge Gaps among LVAD Candidates

, 2019
Education is an important aspect of evaluation and consent for left ventricular assist device (LVAD) candidates. A better understanding of candidate knowledge during the education process can help identify knowledge gaps and improve informed consent ...
J.S. Blumenthal-Barby, Kristin M. Kostick, Meredith Buchberg Trejo, Jerry D. Estep   +3 more
core   +1 more source

Incidence and Determinants of Implantable Cardioverter‐Defibrillator Therapy With Loss of and Impaired Consciousness

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Introduction Implantable cardioverter‐defibrillators (ICDs) are important in the prevention of sudden cardiac death. However, some appropriate ICD therapies may be considered unnecessary, delivered when patients do not experience symptoms of hemodynamic instability such as loss of consciousness.
Alwin B. P. Noordman, Michiel Rienstra, Yuri Blaauw, Bart A. Mulder, Hessel Groenveld, Alexander H. Maass   +5 more
wiley   +1 more source

Apixaban in bridge to transplant and destination LVAD - rationale and study design: the ApixiVAD trial. [PDF]

AIMS Use of novel anticoagulation in mechanical circulatory support is controversial. We report the rationale and design of the ApixiVad pilot trial, a pilot study testing the safety of apixaban as an anticoagulant in patients bridged to transplant ...
Ricardo Deveza, Christopher Hayward, Schnegg, Bruno, Deveza, Ricardo, Hayward, Christopher, Bruno Schnegg   +5 more
core   +1 more source

The Use of a Left Ventricular Assist Device (LVAD) as a Modern Treatment Option for End-Stage Chronic Heart Failure: Clinical Characteristics, Complications, and Short-Term Outcomes

Juvenis Scientia
Introduction. Chronic heart failure (CHF) is one of the leading causes of death worldwide. Although guideline-directed pharmacotherapy can alleviate symptoms, it cannot restore the heart’s pump function.
Timofeev, E. V., Olifirenko, I. S., Zaripov, B. I., Platonova, N. A., Suvorova, A. I.   +4 more
doaj   +1 more source

IL-33/ST2 Pathway and Classical Cytokines in End-Stage Heart Failure Patients Submitted to Left Ventricular Assist Device Support: A Paradoxic Role for Inflammatory Mediators?

Mediators of Inflammation, 2013
Background. Inflammation is a critical process contributing to heart failure (HF). We hypothesized that IL-33/ST2 pathway, a new mechanism regulated during cardiac stress, may be involved in the functional worsening of end-stage HF patients, candidates ...
C. Caselli, A. D'Amico, R. Ragusa, R. Caruso, T. Prescimone, M. Cabiati, S. Nonini, P. Marraccini, S. Del Ry, M. G. Trivella, O. Parodi, D. Giannessi   +11 more
doaj   +1 more source

The interplay between pulsatility, sympathetic regulation and renal physiology: Implications for left ventricular assist devices

Experimental Physiology, EarlyView.
Abstract Left ventricular assist devices have gained traction both as a bridge therapy and as a destination therapy in the management of heart failure. Many of these devices reinstate blood flow in a continuous manner as opposed to the pulsatile flow present in normal physiology.
Tania Warnakulasuriya, Zaid Bahi, Rohit Ramchandra   +2 more
wiley   +1 more source

Stopping LVAD Bleeding [PDF]

Circulation Research, 2017
Left ventricular assist devices (LVADs) are efficient pumps that assist the circulation. They are rapidly evolving and being inserted into an increasing number of patients with advanced heart failure either as a bridge to transplantation or increasingly as destination therapy.
openaire   +2 more sources

LVAD Vasculitis Case Series: Suggestion of a New Fatal LVAD-Related Phenomenon.

JACC. Case reports, 2021
Left ventricular assist devices (LVADs) are surgically implanted mechanical devices indicated for patients with advanced heart failure and are known to come with several complications. Here we present a case series, and review 1 documented report, of LVAD vasculitis, a presumed new LVAD immune/humoral related phenomenon. (Level of Difficulty: Advanced.)
Garcia, Raul Angel, Gaznabi, Safwan, Musoke, Lewis, Osnard, Michael, Balakumaran, Kathir, Armitage, Keith B., Al-Kindi, Sadeer G., Ginwalla, Mahazarin, Abu-Omar, Yasir, Elamm, Chantal A.   +9 more
openaire   +2 more sources

Energetic microdomains and the vascular control of neuronal and muscle excitability: Toward a unified model

The Journal of Physiology, EarlyView.
Abstract figure legend The capillary–mitochondria–ion channel (CMIC) axis scales structural resources to match functional workload. (Left) In settings of restricted energetic capacity (e.g. cortical neurons), sparse capillary networks and modest mitochondrial pools set a lower energetic ceiling, sufficient to support phasic, low‐workload excitability. (
L. Fernando Santana, Scott Earley
wiley   +1 more source

Persistent Fibrosis in Heart Failure With a Reduced Ejection Fraction Linked to Phenotypic Differences in Human Cardiac Fibroblast Populations

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Myocardial fibrosis is prevalent in cardiomyopathies that result in heart failure with reduced ejection fraction. Heart failure with reduced ejection fraction treated with a left ventricular assist device (LVAD) yields hemodynamic unloading ...
Rachel M. Biggs, Yuhua Zhang, Daniel N. Silverman, Catalin F. Baicu, An O. Van Laer, Lauren Wakefield, Devki Bhatt, Stephanie Masline, Lily S. Neff, Arman Kilic, Lucas J. Witer, Brian A. Houston, Samuel J. Coeyman, William J. Richardson, Michael R. Zile, Amy D. Bradshaw   +15 more
doaj   +1 more source